# A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme

> **NCT02344355** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bryan Allen** · enrollment: 90 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Temozolomide
- **RADIATION:** radiation therapy
- **DRUG:** Ascorbic Acid

## Key facts

- **NCT ID:** NCT02344355
- **Lead sponsor:** Bryan Allen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-13
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-12-12

## Collaborators

- Holden Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Gateway for Cancer Research

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02344355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02344355, "A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02344355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*